(Press-News.org) Contact information: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University
Researchers hope newly discovered gene interaction could lead to novel cancer therapies
Scientists from Virginia Commonwealth University Massey Cancer Center have revealed how two genes interact to kill a wide range of cancer cells. Originally discovered by the study's lead investigator Paul B. Fisher, M.Ph., Ph.D., the genes known as mda-7/IL-24 and SARI could potentially be harnessed to treat both primary and metastatic forms of brain, breast, colon, lung, ovary, prostate, skin and other cancers.
In the study, recently published in the online version of the journal Cancer Research, Fisher's team found that forced expression of MDA-7/IL-24 (melanoma differentiation associated gene-7/interlukin-24) stimulates SARI (suppressor of AP-1, induced by interferon) expression in what is known as an autocrine/paracrine loop, which ultimately causes cancer cells to undergo a form of cell suicide known as apoptosis. Autocrine/paracrine loops occur when the expression of a particular gene or its encoded protein causes cells to secrete molecules that bind to surface receptors and force the expression of more of the same protein in an ongoing cycle.
"Many previous studies show that MDA-7/IL-24 can selectively kill diverse cancer cells through multiple mechanisms, but what was unclear was how exactly MDA-7/IL-24 interacted with other genes to promote cancer toxicity," says Fisher, Thelma Newmeyer Corman Endowed Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey Cancer Center, and chairman of the Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine (VIMM) at VCU School of Medicine. "Our study uncovered multiple signaling pathways used by MDA-7/IL-24 that facilitate cancer cell death through the induction of SARI."
Fisher and his team identified an existing combination of receptors, IL-20R1 and IL-20R2, and a discovered new combination of receptors, IL-22R1 and IL-20R1, through which signaling occurs to induce the MDA-7/IL-24 autocrine/paracrine loop. Once activated by the MDA-7/IL-24 protein, these receptors cause both normal and cancer cells to produce and secrete the MDA-7/IL-24 protein, which, in turn, activates SARI. The process was shown to culminate in apoptosis in cancer cells. Normal, healthy cells were not affected in the experiments.
The researchers are now focusing on developing small molecule drugs that induce MDA-7/IL-24 and/or SARI in cancer cells. They have also been experimenting with cancer-selective replicating viruses that seek out cancer cells and infect them with the toxic genes—an approach that has already been successfully employed in a phase 1 clinical trial using engineered viruses that deliver MDA-7/IL-24.
"This study helped us better understand how MDA-7/IL-24 works to kill a broad range of cancer cells through the induction of SARI," says Fisher. "In addition to giving us another target for the development of new therapies, our research also suggests that we may be able to monitor the expression of SARI in order to determine the effectiveness of future therapies under development that target MDA-7/IL-24."
INFORMATION:
Fisher collaborated on this research with Praveen Bhoopathi, Ph.D., postdoctoral research scientist in the Department of Human and Molecular Genetics at the VCU School of Medicine; Swadesh K. Das, Ph.D., instructor in the VCU Department of Human and Molecular Genetics and VIMM member; Devanand Sarkar, M.B.B.S., Ph.D., Harrison Research Scholar and member of the Cancer Molecular Genetics research program at VCU Massey, associate professor in the VCU Department of Human and Molecular Genetics and associate scientific director of cancer therapeutics at VIMM; Luni Emdad, M.B.B.S., Ph.D., member of the Cancer Molecular Genetics research program at VCU Massey, assistant professor in the VCU Department of Human and Molecular Genetics and VIMM member; Santanu Dasgupta, Ph.D., member of the Cancer Molecular Genetics research program at VCU Massey, assistant professor in the VCU Department of Human and Molecular Genetics and VIMM member; and Rupesh Dash, Ph.D., former postdoctoral research scientist in the VCU Department of Human and Molecular Genetics and now assistant professor at the Institute of Life Sciences in Bhubaneshwar, India.
This research was supported by National Institutes of Health grants 5 R01 CA097318, P01 CA104177 and 1 R01CA127641; and, in part, by VCU Massey Cancer Center's NIH-NCI Cancer Center Support Grant P30 CA016059.
The full manuscript of this study is available online at: http://cancerres.aacrjournals.org/content/early/2013/11/26/0008-5472.CAN-13-1062.full.pdf+html
News directors: Broadcast access to VCU Massey Cancer Center experts is available through VideoLink ReadyCam. ReadyCam transmits video and audio via fiber optics through a system that is routed to your newsroom. To schedule a live or taped interview, contact John Wallace, (804) 628-1550.
About VCU Massey Cancer Center
VCU Massey Cancer Center is one of only 68 National Cancer Institute-designated institutions in the country that leads and shapes America's cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It offers the most cancer clinical trials in Virginia and serves patients at 10 locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately to cure cancer. Visit Massey online at http://www.massey.vcu.edu or call 877-4-MASSEY for more information.
About VCU and the VCU Medical Center
Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 31,000 students in 222 degree and certificate programs in the arts, sciences and humanities. Sixty-six of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see http://www.vcu.edu.
Researchers hope newly discovered gene interaction could lead to novel cancer therapies
2013-12-13
ELSE PRESS RELEASES FROM THIS DATE:
Changing chemo not beneficial for metastatic B.C. patients with elevated circulating tumor cells
2013-12-13
Changing chemo not beneficial for metastatic B.C. patients with elevated circulating tumor cells
SAN ANTONIO — For women with metastatic breast cancer who had elevated amounts of circulating tumor cells (CTCs) in their blood after a first line ...
New presurgery combination therapy may improve outcomes for women with triple-negative breast cancer
2013-12-13
New presurgery combination therapy may improve outcomes for women with triple-negative breast cancer
SAN ANTONIO — The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete ...
New combination therapy fails to delay progression of advanced breast cancer
2013-12-13
New combination therapy fails to delay progression of advanced breast cancer
SAN ANTONIO — Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced ...
Bisphosphonate treatment fails to improve outcomes for women with chemoresistant breast cancer
2013-12-13
Bisphosphonate treatment fails to improve outcomes for women with chemoresistant breast cancer
SAN ANTONIO — Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial ...
New presurgery treatment combination more effective for women with triple-negative breast cancer
2013-12-13
New presurgery treatment combination more effective for women with triple-negative breast cancer
SAN ANTONIO — Adding the chemotherapy drug carboplatin and/or the antibody therapy bevacizumab to standard presurgery chemotherapy increased the ...
Additional drug shows promise for women with triple-negative breast cancer
2013-12-13
Additional drug shows promise for women with triple-negative breast cancer
SAN ANTONIO— In a nationwide study of women with "triple-negative" breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy ...
Study shows new paradigm in breast cancer research
2013-12-13
Study shows new paradigm in breast cancer research
Promising drugs put on fast track
MAYWOOD, Ill. – The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during ...
True story: Not everyone lies frequently
2013-12-13
True story: Not everyone lies frequently
Many liars prove honest in their dishonesty
Washington, DC (December 10, 2013) – Does everybody lie? We are taught that this is common sense and that most people tell little white lies. But perhaps this isn't ...
Defending medical oncology to assure quality care for cancer patients
2013-12-13
Defending medical oncology to assure quality care for cancer patients
ESMO releases position paper on the role of medical oncologists in cancer care to ensure patient's access to optimal care
Medical oncologists have a vital role to play in cancer care, particularly ...
Zebrafish help decode link between calcium deficiency and colon cancer
2013-12-13
Zebrafish help decode link between calcium deficiency and colon cancer
ANN ARBOR—A tiny, transparent fish embryo and a string of surprises led scientists to a deeper understanding of the perplexing link between low calcium and colon cancer.
By studying zebrafish ...